BioVie Faces Mixed Phase 2 Results for Bezisterim in Long COVID
BioVie disclosed topline Phase 2 ADDRESS-LC data for bezisterim in Long COVID. Pre-specified subgroup analyses showed meaningful improvements in patients with high symptom burden, while the overall ITT trend was not statistically significant; safety remained favorable. The company also advances its Parkinson’s program, but confirmatory data from a prospective trial remains necessary, keeping clinical and regulatory risk elevated.
View signal analysis